Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
A health ministry panel has agreed that Japan should add a high-dose influenza vaccine for older adults, Sanofi’s Efluelda, to the national immunization program (NIP), citing sufficient efficacy, safety, and cost-effectiveness. At an October 22 meeting, the vaccine evaluation working…
To read the full story
Related Article
- Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+
November 25, 2025
- Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026
November 21, 2025
- Japan to Add High-Dose Flu Vaccine to NIP for Adults Aged 75 and Over
November 21, 2025
- Japan to Pen Fact Sheet for Sanofi’s High-Dose Flu Jab
February 21, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
REGULATORY
- MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
- Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
- Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
February 2, 2026
- MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…